CN1041204C - 用作拓扑酶抑制剂或细胞分化诱导物的五环三萜系化合物 - Google Patents

用作拓扑酶抑制剂或细胞分化诱导物的五环三萜系化合物 Download PDF

Info

Publication number
CN1041204C
CN1041204C CN89107605A CN89107605A CN1041204C CN 1041204 C CN1041204 C CN 1041204C CN 89107605 A CN89107605 A CN 89107605A CN 89107605 A CN89107605 A CN 89107605A CN 1041204 C CN1041204 C CN 1041204C
Authority
CN
China
Prior art keywords
dna
compounds
topozyme
cancer
boswellic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN89107605A
Other languages
English (en)
Chinese (zh)
Other versions
CN1043131A (zh
Inventor
李珏伟
方齐成
王震国
李得华
C·E·库克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International
Original Assignee
RTI International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International filed Critical RTI International
Publication of CN1043131A publication Critical patent/CN1043131A/zh
Application granted granted Critical
Publication of CN1041204C publication Critical patent/CN1041204C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C07C62/06—Saturated compounds containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN89107605A 1988-08-24 1989-08-24 用作拓扑酶抑制剂或细胞分化诱导物的五环三萜系化合物 Expired - Fee Related CN1041204C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23590388A 1988-08-24 1988-08-24
US07/235,903 1988-08-24

Publications (2)

Publication Number Publication Date
CN1043131A CN1043131A (zh) 1990-06-20
CN1041204C true CN1041204C (zh) 1998-12-16

Family

ID=22887334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN89107605A Expired - Fee Related CN1041204C (zh) 1988-08-24 1989-08-24 用作拓扑酶抑制剂或细胞分化诱导物的五环三萜系化合物

Country Status (10)

Country Link
EP (1) EP0431076B1 (cg-RX-API-DMAC10.html)
JP (1) JP2828295B2 (cg-RX-API-DMAC10.html)
KR (1) KR100187738B1 (cg-RX-API-DMAC10.html)
CN (1) CN1041204C (cg-RX-API-DMAC10.html)
AU (1) AU630374B2 (cg-RX-API-DMAC10.html)
CA (1) CA1330944C (cg-RX-API-DMAC10.html)
DE (1) DE68909947T2 (cg-RX-API-DMAC10.html)
DK (1) DK31391A (cg-RX-API-DMAC10.html)
TW (1) TW225990B (cg-RX-API-DMAC10.html)
WO (1) WO1990001937A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201903B4 (de) * 1992-01-24 2004-04-15 Hermann P.T. Prof. Dr.Med. Ammon Pharmazeutische Verwendung von Boswelliasäuren
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
DE4445728A1 (de) * 1994-12-21 1996-06-27 Simmet Th Prof Dr Verwendung von Boswelliasäure zur Behandlung von Hirntumoren
DE19531067A1 (de) † 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
EP1173162A1 (en) * 1999-04-30 2002-01-23 Sabinsa Corporation Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
WO2002085921A2 (de) * 2001-03-01 2002-10-31 Johann Jauch Einfaches verfahren zur synthese von boswelliasäuren und derivaten davon
CN1304007C (zh) * 2002-02-04 2007-03-14 中国医学科学院药物研究所 乙酰乳香酸在制备肿瘤转移抑制剂中的应用
US8028292B2 (en) 2004-02-20 2011-09-27 Sony Computer Entertainment Inc. Processor task migration over a network in a multi-processor system
MX2009013758A (es) * 2007-06-25 2010-03-04 Plant Bioscience Ltd Enzimas que actuan en la sintesis del triterpeno.
DE102008015607A1 (de) * 2008-03-26 2009-10-15 Universität Tübingen Verwendung von Boswelliasäuren und synthetischen Boswelliasäurederivaten zur Hemmung der mikrosomalen Prostaglandin E2 Synthase und des Cathepsin G
EP2408461B1 (de) 2009-03-17 2016-01-27 Ertelt, Herta Verfahren zur extraktion von pflanzlichen harzen sowie dadurch gewonnene extraktionsprodukte und deren verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501734A (en) * 1981-03-06 1985-02-26 Wakunaga Yakuhin Kabushiki Kaisha Promotion of absorption of drugs administered through the alimentary system

Also Published As

Publication number Publication date
AU630374B2 (en) 1992-10-29
AU4303389A (en) 1990-03-23
JP2828295B2 (ja) 1998-11-25
DE68909947D1 (de) 1993-11-18
DK31391D0 (da) 1991-02-22
TW225990B (cg-RX-API-DMAC10.html) 1994-07-01
EP0431076A1 (en) 1991-06-12
JPH04500209A (ja) 1992-01-16
KR900701280A (ko) 1990-12-01
EP0431076A4 (en) 1992-01-15
WO1990001937A1 (en) 1990-03-08
CN1043131A (zh) 1990-06-20
KR100187738B1 (ko) 1999-06-01
DE68909947T2 (de) 1994-02-24
EP0431076B1 (en) 1993-10-13
DK31391A (da) 1991-02-22
CA1330944C (en) 1994-07-26

Similar Documents

Publication Publication Date Title
US5064823A (en) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP4541548B2 (ja) 薬剤組成物及び使用方法
Gordaliza et al. Antitumor properties of podophyllotoxin and related compounds.
US6569842B2 (en) Method of preparing and use of prodrugs of betulinic acid derivatives
CN1100770C (zh) 促进水解的紫杉烷疏水性衍生物
KR20100102092A (ko) 아자시티딘 유사체 및 이들의 용도
CN1646112A (zh) 能作为抗白血病药物的草药分子
CN1774252A (zh) 丙戊酸的磷脂衍生物及其混合物
AU630374B2 (en) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
CN1747964A (zh) 抑制肿瘤生长的药物
JP2022500453A (ja) 線維症、ｎａｓｈ、及び、ｎａｆｌｄを治療する方法での使用のためのトリプトリド、及び、そのプロドラッグ
CN1720054A (zh) 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
WO2016192631A1 (zh) 具有降血脂活性的松香烷型二萜类化合物，其制备方法及用途
JP2009522239A (ja) トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用
WO2004002465A1 (ja) NF-κB阻害剤を含む医薬組成物
CN101049300A (zh) 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
JP2004292426A (ja) 抗菌剤と抗ガン剤
JP2011530539A (ja) 腫瘍形成を抑制する脂質化合物
JP2007063244A (ja) トリテルペン化合物、その製造方法及びそれを有効成分として含有する発癌プロモーション抑制組成物
US20060167097A1 (en) Compositions and uses of Amooranin compounds
US20170267714A1 (en) Natural and synthetic compounds for treating cancer and other diseases
CN1651395A (zh) 冰片脂肪酸酯衍生物及含有该衍生物的制剂
US20050250752A1 (en) Cembranoids with chemopreventive activity
KR100466522B1 (ko) 항암활성을 갖는 ｊ 300 동충하초 추출물 및 이를함유하는 약제학적 조성물
CN121265798A (zh) 一种包含sting激动剂和ido1抑制剂的脂肪酸偶联前药化合物的共组装纳米颗粒、制备及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee